Subtype
Intestinal Carcinoma
CI-CAN-00002922Explore in graph →
409 active trials5 approved drugs22 evidence items
- NCIt
- C227934
Loading cancer entity…
Subtype
CI-CAN-00002922Explore in graph →
Clinical trials
1,268 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (150)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04566393 | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | available | — | — | xCuresINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 4, 2026source: clinicaltrials